Carlsmed, Inc. CARL
17.22 USD -0.15 (-0.86%)
Regular-session close
17.22 0.00 0.00%
After hours · Nov 19, 4:01 PM ET
16.80 Day range 17.77
8.50 52-week range 19.15
- YTD
- +39.43%
- 1 year
- +45.44%
News
globenewswire.com Carlsmed to Participate in Upcoming Investor Conferences CARLSBAD, Calif., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery…
seekingalpha.com Carlsmed: The Reimbursement Reset Is Not Yet In The Numbers Carlsmed is transitioning from a surgeon-driven to a hospital-driven adoption story, catalyzed by new DRG reimbursement effective October 1, 2026. Q3 2026 saw 65% revenue growth, and a gross margin…
benzinga.com These Analysts Boost Their Forecasts On Carlsmed After Strong Q3 Results Carlsmed, Inc. (NASDAQ:CARL) on Tuesday posted upbeat third-quarter results.
benzinga.com These Analysts Boost Their Forecasts On Carlsmed After Strong Q3 Results Carlsmed beats Q3 estimates, raises FY2026 sales guidance to $78M-$80M, and shares jump 19.5% as analysts lift price targets.
benzinga.com Nvidia To $200? Here Are 10 Top Analyst Forecasts For Wednesday Analysts cut targets for AMBQ, TYRA, NVDA, HUBB and CAN; raised CARL and RIOT targets, while downgrading NVDA and RIOT.benzinga.com Truist Securities Maintains Buy on Carlsmed, Raises Price Target to $23 Truist Securities analyst Richard Newitter maintains Carlsmed (NASDAQ:CARL) with a Buy and raises the price target from $20 to $23.
benzinga.com Needham Maintains Buy on Carlsmed, Raises Price Target to $22 Needham analyst David Saxon maintains Carlsmed (NASDAQ:CARL) with a Buy and raises the price target from $17 to $22.
benzinga.com BTIG Maintains Buy on Carlsmed, Raises Price Target to $26 BTIG analyst Ryan Zimmerman maintains Carlsmed (NASDAQ:CARL) with a Buy and raises the price target from $24 to $26.
marketbeat.com Carlsmed Q3 Earnings Call Highlights Carlsmed NASDAQ: CARL raised its full-year revenue outlook after third-quarter sales climbed 65%, as more surgeons adopted its personalized spine surgery products and procedure volume increased.
seekingalpha.com Carlsmed, Inc. (CARL) Q3 2026 Earnings Call Transcript Carlsmed, Inc. (CARL) Q3 2026 Earnings Call Transcript
zacks.com Carlsmed, Inc. (CARL) Reports Q3 Loss, Tops Revenue Estimates Carlsmed, Inc. (CARL) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to a loss of $0.4 per share a year ago.benzinga.com UPDATE: Carlsmed Q3 Adj. EPS $(0.34) Beats $(0.40) Estimate, Sales $21.554M Beat $19.154M Estimate Carlsmed (NASDAQ:CARL) reported quarterly losses of $(0.34) per share which beat the analyst consensus estimate of $(0.40) by 15 percent. This is a 15 percent increase over losses of $(0.40) per…
benzinga.com Carlsmed Q3 2026 Earnings Call Transcript Carlsmed (NASDAQ:CARL) reported third-quarter financial results on Tuesday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is brought to you by…benzinga.com Carlsmed Q3 EPS $(0.45) Misses $(0.40) Estimate, Sales $21.554M Beat $19.154M Estimate Carlsmed (NASDAQ:CARL) reported quarterly losses of $(0.45) per share which missed the analyst consensus estimate of $(0.40) by 12.5 percent. This is a 12.5 percent decrease over losses of $(0.40)…
benzinga.com Carlsmed Raises FY2026 Sales Guidance from $74.000M-$78.000M to $78.000M-$80.000M vs $76.944M Est Carlsmed (NASDAQ:CARL) raises FY2026 sales outlook from $74.000 million-$78.000 million to $78.000 million-$80.000 million vs $76.944 million estimate.
globenewswire.com Carlsmed® Reports Third Quarter 2026 Financial Results and Raises Full-Year Guidance Third quarter 2026 revenue of $21.6 million, representing 65% growth year-over-year Full year 2026 revenue guidance raised to $78 million to $80 million CARLSBAD, Calif., Nov. 10, 2026 (GLOBE…
globenewswire.com Carlsmed, Inc. to Report Third Quarter 2026 Financial Results on November 10, 2026 CARLSBAD, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery…
globenewswire.com Carlsmed Launches aprevo® Lumbar Bi-lateral Posterior System CARLSBAD, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), today announced the U.S. commercial launch of its aprevo® Lumbar Bi-lateral Posterior…
globenewswire.com Carlsmed, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CARLSBAD, Calif., Oct. 02, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery…
globenewswire.com Carlsmed Appoints Tony Jarc as Chief Product and AI Officer CARLSBAD, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery…
globenewswire.com Carlsmed Appoints Richard Heppenstall as Chief Financial Officer CARLSBAD, Calif., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery…
globenewswire.com Carlsmed, Inc. Files Patent Infringement Lawsuit against DeGen Medical CARLSBAD, Calif., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” ), a medical technology company pioneering AI-enabled personalized spine surgery solutions, today filed…
globenewswire.com Carlsmed, Inc. Announces Chief Operating Officer Appointment CARLSBAD, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Carlsmed, Inc. (Nasdaq: CARL) (“Carlsmed” or the “Company”), a medical technology company pioneering AI-enabled personalized spine surgery…
marketbeat.com Carlsmed Eyes Growth as Cervical Launch, Medicare Shift Boost Spine Platform Carlsmed NASDAQ: CARL outlined its strategy for expanding its personalized spine-surgery platform, citing clinical data, reimbursement changes and a planned cervical product launch as potential…
seekingalpha.com Carlsmed, Inc. (CARL) Presents at Bank of America SMID Cap Virtual Conference Transcript Carlsmed, Inc. (CARL) Presents at Bank of America SMID Cap Virtual Conference Transcript
seekingalpha.com Carlsmed, Inc. (CARL) Q2 2026 Earnings Call Transcript Carlsmed, Inc. (CARL) Q2 2026 Earnings Call Transcript
marketbeat.com Carlsmed Q2 Earnings Call Highlights Carlsmed NASDAQ: CARL reported second-quarter 2026 revenue of $18.9 million, up 57% from $12.1 million a year earlier, as growth in its aprevo lumbar platform and contributions from its newer…
zacks.com Carlsmed, Inc. (CARL) Reports Q2 Loss, Beats Revenue Estimates Carlsmed, Inc. (CARL) came out with a quarterly loss of $0.39 per share versus the Zacks Consensus Estimate of a loss of $0.4. This compares to a loss of $1.47 per share a year ago.
globenewswire.com Carlsmed® Reports Second Quarter 2026 Financial Results and Raises Full-Year Guidance Second quarter 2026 revenue of $18.9 million, representing 57% growth year-over-year Full year 2026 revenue guidance raised to $74 million to $78 million CARLSBAD, Calif., Aug. 05, 2026 (GLOBE…
